Apimeds Pharmaceuticals US Inc. (APUS), a subsidiary of Kospi-listed Inscobee Inc., said May 12 that it raised $13.5 million from its stock sale on the NYSE American exchange May 9 through an offering of 3.375 million shares at $4 per share. Hopewell, N.J.-based APUS is the second pharmaceutical company with Asian ties to float shares on the U.S. market this year.

Sevenless Therapeutics Ltd. has disclosed son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, pain, dementia, Noonan syndrome, Parkinson's disease and neurofibromatosis type 1.

N-Methyl-D-aspartate (NMDA)-subtype glutamate receptors are an attractive target for chronic pain and posttraumatic stress disorder treatments.

Cannabinoid CB1 receptors have been a potential target for nonopioid-based pain treatment, but actually targeting the pathway has been hindered by issues with tolerance and unwanted CNS side effects. Peripherally selective CB1 agonists developed to overcome these problems have not fully resolved these issues, meaning the peripheral selectivity has to be substantially enhanced.

Virginia Commonwealth University has synthesized nitrogen-walk derivatives of NAN acting as µ-opioid receptor modulators reported to be useful for the treatment of pain, opioid dependency and neurological disorders.

Shanghai Wennai Pharmaceutical Technology Co. Ltd. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of acute and chronic pain.

Navega Therapeutics Inc. has received a $4 million Translational Science grant from the California Institute for Regenerative Medicine (CIRM) to support its work addressing neuropathic pain. The grant will fund the final preclinical development studies of NT-Z001 leading to an IND submission.